News Feed Item

Personal Genome Diagnostics' Circulating Tumor DNA Technology Highlighted In Landmark Study

--New Publication in Science Translational Medicine Confirms Utility of Cell-Free Circulating Tumor DNA (ctDNA) for Cancer Drug Development and Diagnosis--

BALTIMORE, Md., Feb. 19, 2014 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, reported that its proprietary technology was used in a major new study being published today in the journal Science Translational Medicine. The study, "Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies," assessed the utility of cell-free circulating tumor DNA (ctDNA) for cancer detection and monitoring across multiple patient populations and applications. The authors conclude that ctDNA is a broadly applicable, sensitive and specific biomarker that can be used for a variety of clinical and research purposes in patients with different types of cancer.1

Some of the findings reported today were analyzed using PGDx's proprietary PARE technology, an ultrasensitive technique that enables whole genome identification of changes in tumor-specific ctDNA. The new findings are consistent with previous publications by PGDx researchers and further validate the company's work using ctDNA-based analyses for cancer research and drug development.

"This landmark study further validates the utility of circulating DNA as a biomarker in cancer therapeutic research and treatment," noted Mark Sausen, PhD, a lead author of the new study and Director of R&D at PGDx. Dr. Sausen was one of the first researchers to use genome-wide analyses of ctDNA to identify newly-acquired genetic alterations associated with resistance to targeted therapies.

Dr. Sausen added, "At PGDx, we have experienced a surge of interest in ctDNA-based analyses and are now using our PARE and related technologies to routinely perform genetic analyses on ctDNA, thereby obviating the need for invasive biopsies. Genomic analyses conducted using ctDNA produce a great deal of information, including detection of structural genomic alterations and point mutations, which makes them very valuable for the development of targeted cancer therapies."

Unlike other approaches, which can detect point mutations in ctDNA, PARE (Personalized Analysis of Rearranged Ends) can also detect structural changes, including the genomic amplifications and rearrangements that are critical for guiding cancer treatment. PGDx has licensed exclusive rights to the PARE technology from Johns Hopkins University.

The study in Science Translational Medicine addressed several topics related to ctDNA. The first assessed the extent to which ctDNA could be detected in different cancer populations at various stages of disease. It found ctDNA was detectable in many, but not all types of advanced solid tumor cancers, as well as in many individuals with earlier-stage localized tumors. The study also found that cell-free ctDNA often was detectable in patients who lacked circulating tumor cells, providing further validation of PGDx's ctDNA approach.

The new study also found that ctDNA could be used to identify known and novel genetic mutations associated with drug resistance in patients with colorectal cancer. PGDx has previously published research showing that its PARE ctDNA approach2,3, which can detect structural alterations in ctDNA with high sensitivity and specificity, was able to identify novel mechanisms of acquired drug resistance from the blood of a colorectal cancer patient being treated with targeted therapy. These analyses enabled the new genetic alteration to be identified before any clinical signs of drug resistance were evident, providing early warning that a change in therapy was needed.

Antony Newton, Chief Commercial Officer of PGDx, added, "This new study confirms the value of our expertise in the application of cell-free circulating tumor DNA technologies. We are already offering these technologies for both prospective and retrospective clinical trial applications and expect this new study will accelerate the growing interest in the use of ctDNA for drug development."

Along with Dr. Sausen, co-authors of the new study include PGDx co-founders and Johns Hopkins cancer researchers Dr. Luis Diaz and Dr. Victor Velculescu.

1. Science Translational Medicine. 2014 February 19; 6 (224): Detection of circulating tumor DNA in early- and late-stage human malignancies. C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang, N. Agrawal, B. R. Bartlett, H. Wang, B. Luber, R. M. Alani, E. S. Antonarakis, N. S. Azad, A. Bardelli, H. Brem, J. L. Cameron, C. C. Lee, L. A. Fecher, G. L. Gallia, P. Gibbs, D. Le, R. L. Giuntoli, M. Goggins, M. D. Hogarty, M. Holdhoff, S.-M. Hong, Y. Jiao, H. H. Juhl, J. J. Kim, G. Siravegna, D. A. Laheru, C. Lauricella, M. Lim, E. J. Lipson, S. K. N. Marie, G. J. Netto, K. S. Oliner, A. Olivi, L. Olsson, G. J. Riggins, A. Sartore-Bianchi, K. Schmidt, l.-M. Shih, S. M. Oba-Shinjo, S. Siena, D. Theodorescu, J. Tie, T. T. Harkins, S. Veronese, T.-L. Wang, J. D. Weingart, C. L. Wolfgang, L. D. Wood, D. Xing, R. H. Hruban, J. Wu, P. J. Allen, C. M. Schmidt, M. A. Choti, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, N. Papadopoulos, L. A. Diaz Jr.

2. Oncotarget. 2013 October; 4(10): 1856–1857. PMCID: PMC3858570. Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. Luis A. Diaz, Jr., Mark Sausen, George A. Fisher, and Victor E. Velculescu.

3. Cancer Discovery. 2013 June; 3 (6): 658-73. doi: 10.1158/2159-8290.CD-12-0558. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr., Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S.

About Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) provides advanced cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company uses advanced genomic methods and its deep expertise in cancer biology to identify and characterize the unique genomic alterations in tumors.  PGDx's proprietary methods for genome sequencing and analysis are complemented by its extensive experience in cancer genomics and clinical oncology. The founders of PGDx, Luis Diaz, MD, and Victor Velculescu, MD, PhD, are internationally recognized leaders in cancer genomics at Johns Hopkins University who have extensive experience in the practical application of advanced genomic technologies to drug development and clinical practice. PGDx's CLIA-certified facility provides personalized cancer genome analyses to patients and their physicians. For more information, visit www.personalgenome.com.


Personal Genome Diagnostics


Antony Newton

BLL Partners, LLC

Chief Commercial Officer 

Barbara Lindheim

410 849-9189

212 584-2276

[email protected] 

[email protected]

SOURCE Personal Genome Diagnostics Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Cloud based infrastructure deployment is becoming more and more appealing to customers, from Fortune 500 companies to SMEs due to its pay-as-you-go model. Enterprise storage vendors are able to reach out to these customers by integrating in cloud based deployments; this needs adaptability and interoperability of the products confirming to cloud standards such as OpenStack, CloudStack, or Azure. As compared to off the shelf commodity storage, enterprise storages by its reliability, high-availabil...
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
Complete Internet of Things (IoT) embedded device security is not just about the device but involves the entire product’s identity, data and control integrity, and services traversing the cloud. A device can no longer be looked at as an island; it is a part of a system. In fact, given the cross-domain interactions enabled by IoT it could be a part of many systems. Also, depending on where the device is deployed, for example, in the office building versus a factory floor or oil field, security ha...
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will discuss how customers are able to achieve a level of transparency that e...
SYS-CON Events announced today that Transparent Cloud Computing (T-Cloud) Consortium will exhibit at the 19th International Cloud Expo®, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. The Transparent Cloud Computing Consortium (T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data proces...
Governments around the world are adopting Safe Harbor privacy provisions to protect customer data from leaving sovereign territories. Increasingly, global companies are required to create new instances of their server clusters in multiple countries to keep abreast of these new Safe Harbor laws. Is it worth it? In his session at 19th Cloud Expo, Adam Rogers, Managing Director of Anexia, Inc., will discuss how to keep your data legal and still stay in business.
Successful transition from traditional IT to cloud computing requires three key ingredients: an IT architecture that allows companies to extend their internal best practices to the cloud, a cost point that allows economies of scale, and automated processes that manage risk exposure and maintain regulatory compliance with industry regulations (FFIEC, PCI-DSS, HIPAA, FISMA). The unique combination of VMware, the IBM Cloud, and Cloud Raxak, a 2016 Gartner Cool Vendor in IT Automation, provides a co...
Today every business relies on software to drive the innovation necessary for a competitive edge in the Application Economy. This is why collaboration between development and operations, or DevOps, has become IT’s number one priority. Whether you are in Dev or Ops, understanding how to implement a DevOps strategy can deliver faster development cycles, improved software quality, reduced deployment times and overall better experiences for your customers.
Donna Yasay, President of HomeGrid Forum, today discussed with a panel of technology peers how certification programs are at the forefront of interoperability, and the answer for vendors looking to keep up with today's growing industry for smart home innovation. "To ensure multi-vendor interoperability, accredited industry certification programs should be used for every product to provide credibility and quality assurance for retail and carrier based customers looking to add ever increasing num...
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and ...
@ThingsExpo has been named the Top 5 Most Influential M2M Brand by Onalytica in the ‘Machine to Machine: Top 100 Influencers and Brands.' Onalytica analyzed the online debate on M2M by looking at over 85,000 tweets to provide the most influential individuals and brands that drive the discussion. According to Onalytica the "analysis showed a very engaged community with a lot of interactive tweets. The M2M discussion seems to be more fragmented and driven by some of the major brands present in the...
Apache Hadoop is a key technology for gaining business insights from your Big Data, but the penetration into enterprises is shockingly low. In fact, Apache Hadoop and Big Data proponents recognize that this technology has not yet achieved its game-changing business potential. In his session at 19th Cloud Expo, John Mertic, director of program management for ODPi at The Linux Foundation, will explain why this is, how we can work together as an open data community to increase adoption, and the i...
Machine Learning helps make complex systems more efficient. By applying advanced Machine Learning techniques such as Cognitive Fingerprinting, wind project operators can utilize these tools to learn from collected data, detect regular patterns, and optimize their own operations. In his session at 18th Cloud Expo, Stuart Gillen, Director of Business Development at SparkCognition, discussed how research has demonstrated the value of Machine Learning in delivering next generation analytics to impr...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of So...